| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 10.440 | 16.404 | 12.467 | 19.423 | 13.185 | 14.794 | 15.524 | 15.966 | - | 14.465 |
| Total Income - EUR | 10.440 | 18.630 | 12.467 | 21.357 | 14.244 | 14.794 | 15.524 | 15.966 | - | 14.465 |
| Total Expenses - EUR | 8.343 | 11.001 | 5.377 | 7.830 | 5.056 | 6.472 | 4.278 | 6.899 | - | 4.736 |
| Gross Profit/Loss - EUR | 2.097 | 7.630 | 7.090 | 13.527 | 9.188 | 8.322 | 11.245 | 9.067 | - | 9.730 |
| Net Profit/Loss - EUR | 1.782 | 7.070 | 6.716 | 12.886 | 8.760 | 7.878 | 10.913 | 8.706 | - | 9.585 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 |
Check the financial reports for the company - Endocrinia Plus Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 5.772 | 1.705 | 179 | 176 | 173 | 169 | 721 | 724 | - | 717 |
| Current Assets | 4.976 | 11.100 | 13.406 | 13.682 | 22.543 | 23.962 | 27.461 | 25.745 | - | 15.081 |
| Inventories | 440 | 436 | 428 | 420 | 412 | 404 | 395 | 397 | - | 404 |
| Receivables | 0 | 192 | 130 | 431 | 421 | 0 | 3 | 0 | - | 324 |
| Cash | 4.536 | 10.473 | 12.848 | 12.831 | 21.709 | 23.558 | 27.063 | 25.348 | - | 14.354 |
| Shareholders Funds | 5.229 | 12.246 | 12.366 | 13.138 | 21.644 | 23.685 | 27.705 | 25.851 | - | 14.362 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | - | 40 |
| Debts | 5.519 | 559 | 1.219 | 719 | 1.071 | 446 | 478 | 617 | - | 1.437 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Endocrinia Plus Srl